Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment
2006

Interleukin-1 and Cancer Progression

publication Evidence: moderate

Author Information

Author(s): Lewis Anne M, Varghese Sheelu, Xu Hui, Alexander H Richard

Primary Institution: National Cancer Institute, Bethesda, Maryland, USA

Hypothesis

The review focuses on the role of interleukin-1 in tumor progression and the potential of interleukin-1 receptor antagonist as a therapeutic agent in cancer treatment.

Conclusion

Interleukin-1 promotes tumor growth, angiogenesis, and metastasis, and its inhibition may provide a novel therapeutic approach in cancer treatment.

Supporting Evidence

  • High concentrations of interleukin-1 in tumors are linked to worse patient outcomes.
  • Interleukin-1 receptor antagonist has shown promise in reducing tumor growth in animal models.
  • Chronic inflammation is associated with the development of many cancers.

Takeaway

Interleukin-1 is a substance in the body that can help tumors grow, but blocking it might help treat cancer.

Methodology

The review summarizes existing studies on interleukin-1's role in cancer and the effects of its antagonist.

Limitations

The review does not provide new experimental data but summarizes existing literature.

Digital Object Identifier (DOI)

10.1186/1479-5876-4-48

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication